Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Zendy

Mark E. Robson | Zendy; SeockAh Im | Zendy; Elżbieta Senkus | Zendy; Binghe Xu | Zendy; Susan M. Domchek | Zendy; Norikazu Masuda | Zendy; Suzette Delaloge | Zendy; Wěi Li | Zendy; Nadine Tung | Zendy; Anne Armstrong | Zendy; Wenting Wu | Zendy; Carsten Goessl | Zendy; Sarah Runswick | Zendy; Pierfranco Conté | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Author(s) -

Mark E. Robson,

SeockAh Im,

Elżbieta Senkus,

Binghe Xu,

Susan M. Domchek,

Norikazu Masuda,

Suzette Delaloge,

Wěi Li,

Nadine Tung,

Anne Armstrong,

Wenting Wu,

Carsten Goessl,

Sarah Runswick,

Pierfranco Conté

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1706450

Subject(s) - olaparib , medicine , oncology , parp inhibitor , hazard ratio , brca mutation , metastatic breast cancer , breast cancer , eribulin , cancer , confidence interval , gene , polymerase , poly adp ribose polymerase , biochemistry , chemistry

Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research